ESG

Adaptive posted a 55% revenue surge in 2025, fueled by its clonoSEQ cancer test. Now, the firm is charting a clear course to company-wide profitability.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

With FDA alignment for its rapid postpartum depression therapy and new trials for anxiety, Reunion Neuroscience is pioneering a new era of mental health.

KEY Investment Partners acquires BellRock Brands' portfolio out of receivership, launching MM Brands with Joe Bayern to lead a wellness-focused revival.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

WindRose and Francisco Partners invest in Avalon, signaling a major shift toward tech-driven management of the multi-billion dollar diagnostic testing market.

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Palladyne AI launches its IQ 2.0 software, a low-code platform aiming to overhaul defense manufacturing in line with new government mandates.

Teladoc Health's enhanced service integrates specialist consults and data analytics, moving beyond urgent care to reshape healthcare costs and patient outcomes.

A new joint venture will build a massive solar tracker factory in Saudi Arabia, aiming to accelerate the Kingdom's green energy goals and create 2,000 jobs.

The food services giant is the only company in its sector to earn CDP's top climate rating, signaling a major shift in industry sustainability standards.

French aerospace giant Dassault Aviation partners with Harmattan AI, aiming to lead Europe's charge in the global race for sovereign, AI-driven warfare.

As WD-40 leaders prepare for the ICR Conference, investors weigh strong growth plans against a recent earnings miss and a major brand overhaul.

Economist Jim Rickards says the U.S. is on the verge of a mineral boom, but a complex web of new rules and legal fights complicates the path forward.

At CES 2026, Chinese robotics firm RoboCT unveiled a bold strategy to turn exoskeletons from medical aids into everyday 'new organs' for all.

A private highway funds its own police force, boasting fewer crashes and huge economic benefits. Is this a model for the future or a risky precedent?

A massive partnership aims to build gigawatt-scale data centers for OpenAI's 'Stargate' project, merging AI ambition with immense energy demands.

With drug costs soaring, industry veteran Ritu Malhotra joins Illuminate Rx, promising to disrupt the opaque PBM market. But can transparency truly win?

Eason Technology is betting its future on Chinese real estate with a deal that could dilute shareholders by over 80%. But can it get past the NYSE?